Rang and Dale’s Pharmacology Flashcards E-Book

Name: Rang and Dale’s Pharmacology Flashcards E-Book
Price: 2590 ISK
Availability: InStock
Author: Yoon Kong Loke; Katharina Mattishent
ISBN: 9780702082139

Höfundar: Yoon Kong Loke; Katharina Mattishent (Útgáfa: 2)

Kaup valmöguleikar

Organized in conjunction with Rang and Dale’s Pharmacology 9th edition, Rang & Dale's Pharmacology Flashcards helps you review what you learn in class and reinforce essential information. One side of each flashcard features a diagram of the pathophysiological processes including the drug class at the top of the card. The back of the card details essential information for that drug class including actions, mechanism of action, pharmacokinetic aspects, adverse effects, the names of related drugs and important aspects of clinical use.

Completely updated with the latest knowledge in pharmacology and clinical useNew chapter on drugs used for eye and skin conditions, new coverage of clinical use of biopharmaceuticals in a wide range of conditions, and a concise explanation of the rapidly growing impact of pharmacogeneticsClinical correlations help you apply information to real-life situationsCompact and efficient size make it easy to carry selected cards with you and study on the goA perfect study aid and complement to Rang & Dale’s Pharmacology, 9th Edition–—ideal for exam preparationStudent Consult™ eBook version included with purchase.

Nánar um bókina

Útgefandi: Elsevier Limited (UK)

ISBN: 9780702082139

Print ISBN: 9780702079054

Format: ePub

Útgáfa: 2

Höfundar: Yoon Kong Loke; Katharina Mattishent

Tungumál: English

Útgefið: 2019-11-15

Prent takmörkun á líftíma: 10

Flokkar: Heilbrigðisvísindi

Efnisflokkar: Læknisfræði › Lyfjafræði

Kaflar

Instructions for online access
Cover image
Title Page
Table of Contents
Copyright
How to Use These Cards
Preface
Acknowledgements
Abbreviations
Section I Cholinergic pharmacology
1.01 Muscarinics – Eye
1.02 Antimuscarinics – Eye
1.03 Antimuscarinics – Gastrointestinal
1.04 Antimuscarinics – Bladder
1.05 Neuromuscular Blocker
1.06 Neuromuscular Blocker
1.07 Peripheral Anticholinesterases
1.08 Nicotinic Partial Agonists
Section II Noradrenergic pharmacology
2.01 β2-Receptor Agonist
2.02 β1-Receptor Antagonist
2.03 α- and β-Receptor Agonists
2.04 α1-Receptor Antagonist
2.05 β1-Receptor Agonist
2.06 α1-Receptor Agonist
2.07 Drugs That Release Noradrenaline
2.08 Selective β3-Adrenoceptor Agonist
2.09 α2-Agonist Prodrug
2.10 DOPA Decarboxylase Inhibitor
Section III Inflammation and anti-inflammatory drugs
3.01 NSAIDs
3.02 NSAIDs
3.03 NSAIDs
3.04 COX-2 Inhibitors
3.05 DMARDs
3.06 DMARDs
3.07 DMARDs
3.08 Uricosuric Agents
3.09 Antigout: Colchicine
Notes
Section IV Drugs affecting the immune response
4.01 Calcineurin Inhibitors
4.02 Antiproliferative Immunosuppressant
4.03 Antiproliferative Immunosuppressant
4.04 Antiproliferative Antibiotic
4.05 Glucocorticoids
4.06 TNF Inhibitors
4.07 Antibodies Against CD20
4.08 Monoclonal Antibodies (non-CD20)
4.09 Interleukin Inhibitors
4.10 JAK
4.11 Non-Sedating Antihistamines
4.12 Sedating Antihistamine
4.13 Drugs Affecting the Immune Response
Section V Antidysrhythmic drugs
5.01 Class Ia Antidysrhythmic
5.02 Class Ic Antidysrhythmic
5.03 Class II Antidysrhythmic
5.04 Class III Antidysrhythmic
5.05 Class IV Antidysrhythmic
5.06 Adenosine Receptor Agonists
5.07 Cardiac Glycoside
Section IV The vascular system
6.01 ACE Inhibitors
6.02 Angiotensin Antagonists
6.03 Calcium Channel Blockers
6.04 Potassium Channel Activator
6.05 Hydralazine
6.06 Endothelin Antagonist
Section VII The heart
7.01 Nitrates
7.02 Ivabradine
7.03 Ranolazine
Section VIII Drugs for eye and skin conditions
8.01 Glaucoma Eyedrops
Notes
8.02 VEGF Inhibitors
Notes
8.03 Retinoids
8.04 Treatment of Psoriasis
Notes
8.05 Skin Parasites
Notes
Section IX Atherosclerosis and lipoprotein metabolism
9.01 HMG-CoA Reductase Inhibitors
9.02 Fibrates
9.03 PCSK9 Inhibitors
9.04 Cholesterol-Absorption Inhibitors
9.05 Cholesterol-Absorption Inhibitors
Section X Haemostasis and thrombosis
10.01 Irreversible COX-1 Inhibitor
10.02 Adenosine (P2Y12) Antagonists
10.03 GPIIb/IIIa Receptor Antagonists
10.04 Other Antiplatelets Drugs
10.05 Plasminogen Activators
10.06 Plasminogen Inhibitor
10.07 Anticoagulants
10.08 Anticoagulants
10.09 Anticoagulants
10.10 Direct Oral Anticoagulants
Section XI Haemopoietic system and treatment of anaemia
11.01 Haematinic Agents
11.02 Haematinic Agents
11.03 Haematinic Agents
11.04 Haemopoietic Growth Factors
11.05 Haemopoietic Growth Factors
Section XII Respiratory system
12.01 β2-Receptor Agonists
12.02 Xanthines
12.03 Leukotriene Antagonists
12.04 Inhaled Muscarinic Antagonists
12.05 Inhaled Glucocorticoids
12.06 Inhibitor of Mast Cells
12.07 Inhibition of Interleukin-5
12.08 Anti-Fibrotic Agents
Notes
Section XIII Kidney
13.01 Loop Diuretics
13.02 Thiazide Diuretics
13.03 Potassium-Sparing Diuretics
13.04 Osmotic Diuretic
Section XIV Gastrointestinal tract drugs
14.01 H2 Antagonist
14.02 Proton Pump Inhibitors
14.03 Mucosal Protectants
14.04 Antacids
14.05 Prostaglandin E Agonist
14.06 5-HT3 Antagonists – Antiemetics
14.07 Other Antiemetics
14.08 Osmotic Laxatives
14.09 Bulk Laxatives
14.10 Stimulant Laxatives
14.11 Faecal Softeners
14.12 Other Drugs for Constipation
14.13 Antidiarrhoeal Agent
14.14 Other Drugs That Reduce GI Motility
Section XV The control of blood glucose and drug treatment of diabetes mellitus
15.01 Insulin
15.02 Sulfonylureas
15.03 Biguanides
15.04 Meglitinides
15.05 Glucagon-Like Peptide-1 Agonists
15.06 Dipeptidyl Peptidase Inhibitors
15.07 SGLT-2 Inhibitors
15.08 α-Glucosidase Inhibitors
15.09 Glucagon
Section XVI The pituitary and the adrenal cortex
16.01 Hypothalamic Hormones
16.02 Hypothalamic Hormones
16.03 Anterior Pituitary Hormones
16.04 Posterior Pituitary Hormones
16.05 Mineralocorticoid
Section XVII The thyroid
17.01 Thyroid Hormone Suppression
17.02 Thyroid Hormone Replacement
Section XVIII Bone metabolism
18.01 Antiresorptive Drugs
18.02 Antiresorptive Drugs
18.03 Antiresorptive Drugs
18.04 Antiresorptive Drugs
18.05 Anabolic Agents
18.06 Vitamin D Preparations
Section XIX Reproductive system
19.01 Oestrogens and Anti-Oestrogens
19.02 Progestogens and Anti-Progestogens
19.03 Combined Oral Contraceptive Pill
19.04 Gonadotrophins
19.05 Uterine Stimulants
19.06 Uterine Stimulants
19.07 Uterine Stimulants
19.08 Oxytocin Antagonist
19.09 Male Sex Hormone
19.10 Anti-Androgens
19.11 Phosphodiesterase Type V Inhibitors
Section XX Neurodegenerative disorders
20.01 Drugs Used in Parkinson's Disease
20.02 Drugs Used in Parkinson's Disease
20.03 Drugs Used in Parkinson's Disease
20.04 Drugs Used in Parkinson's Disease
20.05 Drugs Used in Parkinson's Disease
20.06 Drugs Used in Parkinson's Disease
20.07 Drugs Used in Alzheimer's Disease
20.08 Drugs Used in Alzheimer's Disease
20.09 Drugs Used in Multiple Sclerosis
Notes
Section XXI General anaesthetics
21.01 Inhalational Agents
21.02 Inhalational Agents
21.03 Intravenous Anaesthesia
Section XXII Anxiolytics and hypnotic drugs
22.01 Benzodiazepines
22.02 Z-drugs
22.03 Partial Serotonin Agonist
22.04 Other Insomnia Drugs
Notes
Section XXIII Antipsychotic drugs
23.01 First-Generation Antipsychotics
23.02 First-Generation Antipsychotics
23.03 First-Generation Antipsychotics
23.04 Second-Generation Antipsychotics
23.05 Second-Generation Antipsychotics
23.06 Second-Generation Antipsychotics
23.07 Second-Generation Antipsychotics
23.08 Second-Generation Antipsychotics
Section XXIV Antidepressant drugs
24.01 Tricyclics
24.02 SSRIs
24.03 SNRIs
24.04 Noradrenaline Reuptake Inhibitor
24.05 Monoamine Oxidase Inhibitors
24.06 α-Adrenoceptor & 5-HT Receptor Antagonist
24.07 Dopamine Reuptake Inhibitor
24.08 Drugs for Bipolar Disorder
24.09 Drugs for Bipolar Disorder
Notes
Section XXV Antiepileptic drugs
25.01 Sodium Channel Inhibitors
25.02 T-Type Calcium Channel Blockers
25.03 Broad-Spectrum Antiepileptic
25.04 Benzodiazepines
25.05 Barbiturates
25.06 Broad-Spectrum Antiepileptic
25.07 Broad-Spectrum Antiepileptic
25.08 AMPA Receptor Blockers
25.09 Broad-Spectrum Antiepileptic
25.10 Other Anticonvulsants
Section XXVI Analgesic drugs
26.01 Opioid Drugs
26.02 Opioid Drugs
26.03 Opioid Drugs
26.04 Opioid Drugs
26.05 Drugs Used for Neuropathic Pain
26.06 Drugs Used for Neuropathic Pain
26.07 Drugs Used for Neuropathic Pain
26.08 Other Analgesic Drugs
Notes
Section XXVII Psychoactive drugs
27.01 Psychomotor Stimulants
27.02 Psychomotor Stimulants
27.03 Psychomotor Stimulants
27.04 CNS Depressants
27.05 Other Psychoactive Drugs
Notes
27.06 Major Psychedelic Drugs
Section XXVIII Local anaesthetics
28.01 Rapid-Onset LAs
28.02 Slow- and Medium-Onset LAs
28.03 Topical LA
Section XXIX Antibacterial drugs
29.01 Beta-Lactam Antibiotics
29.02 Beta-Lactam Antibiotics
29.03 Beta-Lactam Antibiotics
29.04 Blockers of Peptidoglycan Synthesis
29.05 Bacterial Protein Synthesis Blockers
29.06 Bacterial Protein Synthesis Blockers
29.07 Bacterial Protein Synthesis Blockers
29.08 Bacterial Protein Synthesis Blockers
29.09 Bacterial Protein Synthesis Blockers
29.10 Antibiotics Affecting Topoisomerase
29.11 Blockers of Folate Synthesis/Action
29.12 Other Antibacterial Drugs
Notes
29.13 Antimycobacterials for Tuberculosis
Notes
29.14 Antimycobacterials for Leprosy
Notes
Section XXX Antiviral drugs
30.01 Reverse Transcriptase Inhibitors
30.02 Reverse Transcriptase Inhibitors
30.03 Protease Inhibitors
30.04 DNA Polymerase Inhibitors
30.05 Neuraminidase Inhibitors
30.06 Biopharmaceutical Antivirals
Notes
30.07 Drugs Used in HIV
Notes
30.08 Drugs Used in Hepatitis
Notes
Section XXXI Antiprotozoal drugs
31.01 Blood Schizonticides – Malaria
31.02 Tissue Schizonticide – Malaria
31.03 Folate Inhibitors – Malaria
31.04 Artemisinin Derivatives – Malaria
31.05 Treatment of Amoebiasis
31.06 Other Antiprotozoal Drugs
Section XXXII Antifungal drugs
32.01 Antifungal Antibiotics
32.02 Synthetic Antifungal Drugs – Azoles
32.03 Other Antifungal Drugs
Section XXXIII Mebendazole
33.01 Anthelminthic Drugs
33.02 Anthelminthic Drugs
33.03 Anthelminthic Drugs
33.04 Anthelminthic Drugs
33.05 Anthelminthic Drugs
33.06 Anthelminthic Drugs
33.07 Anthelminthic Drugs
Section XXXIV Anticancer drugs
34.01 Alkylating Agents and Similar Drugs
34.02 Antimetabolites
34.03 Cytotoxic Antibiotics
34.04 Plant Derivatives
34.05 Hormones
34.06 Protein Kinase Inhibitors
34.07 Monoclonal Antibodies
34.08 Anticancer Drugs
Section XXXV General principles
35.01 Agonists and Antagonists
35.02 Affinity
35.03 Efficacy
35.04 Competitive Antagonism
Section XXXVI Genetic variation and personalized medicine
36.01 Drug Efficacy
36.02 Drug Safety
36.03 Pharmacokinetics
Section XXXVII Absorption and distribution of drugs
37.01 Lipid Solubility and Ionization
37.02 Routes of Drug Administration
37.03 Bioavailability
37.04 Measurement of Bioavailability
37.05 Non-Target Binding of Drugs
37.06 Volume of Distribution, Vd
Section XXXVIII Drug metabolism and excretion
38.01 Phase I and Phase II Metabolism
38.02 Cytochrome P450 System
38.03 P450 Induction and Inhibition
38.04 Renal Excretion of Drugs
38.05 Other Routes of Excretion
Section XXXIX Pharmacokinetics
39.01 First-Order Elimination
39.02 Zero-Order Elimination
39.03 Plasma Half-Life
39.04 Clearance
Drug Index